4 terminated, 1 unknown. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 4, Unknown 1 |
| Phase 1 | 3 | Terminated 2, Unknown 1 |
Follow Proacta, Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors PR610 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | Proacta, Incorporated | 33 | 2012-08-01 | 2014-06-16 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PR104 - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Proacta, Incorporated | 50 | 2010-01-01 | 2012-08-31 |
| Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) PR104, docetaxel, Granulocyte colony-stimulating factor - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Proacta, Incorporated | 42 | 2009-03-01 | 2013-01-10 |
| Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | Proacta, Incorporated | 14 | 2009-03-01 | 2013-08-23 |
| PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer PR104, F-18-fluoromisonidazole - Lung Cancer | Phase 2 | Terminated | Proacta, Incorporated | 5 | 2007-08-01 | 2012-12-10 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Carcinoma, Hepatocellular (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Small Cell Lung Carcinoma (1)
PR-104 (2) · Docetaxel (1) · Granulocyte Colony-Stimulating Factor (1) · Sorafenib (1) · fluoromisonidazole (1)
United States (5) · New Zealand (2) · Canada (1) · Hong Kong (1) · Singapore (1) · Taiwan (1)